Shree Kurup, MD
Ophthalmology · Cleveland, OHNPI 1437103389
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $24,938 of the $36,435 with a category attached, or 68.4%. 19 manufacturers reported payments, led by Novartis at 48.7% of the total. Reporting peaked in 2021 at $15,354 and has fallen 88.5% since, to $1,769 in 2025. Among ophthalmology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 165 payments — averaging $220.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$18K
- Bausch & Lomb Americas Inc.$10K
- Alimera Sciences, Inc.$2K
- AbbVie$2K
- Regeneron Healthcare Solutions, Inc.$994
- Eyepoint US, Inc.$695
- plus $3K from 13 others
Across 55 payments — averaging $2791.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$49K
- Alimera Sciences, Inc.$37K
- Genentech, Inc.$32K
- Regeneron$28K
- ANI Pharmaceuticals, Inc.$8K
What the payments were for
- Consulting fees$24,93868%
- Speaking & faculty fees$4,61313%
- Food & beverage$6,87119%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 4 | $17,738 |
| Bausch & Lomb Americas Inc. | 12 | $9,998 |
| Alimera Sciences, Inc. | 33 | $2,192 |
| AbbVie(2 entities) | 13 | $1,780 |
| Regeneron Healthcare Solutions, Inc. | 30 | $994 |
| Eyepoint US, Inc. | 11 | $695 |
| Harrow Eye, LLC | 6 | $521 |
| Mallinckrodt Hospital Products Inc. | 7 | $453 |
| Apellis Pharmaceuticals, Inc. | 11 | $443 |
| Coherus Oncology, Inc. | 4 | $381 |
| Astellas Pharma US Inc | 9 | $367 |
| Genentech USA, Inc. | 9 | $208 |
| Sandoz | 3 | $184 |
| Regeneron | 2 | $175 |
| Alcon | 3 | $105 |
| ANI Pharmaceuticals, Inc. | 3 | $54 |
| Mallinckrodt Enterprises LLC | 1 | $52 |
| Halozyme Inc | 2 | $49 |
| Tarsus Pharmaceuticals, Inc. | 2 | $47 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,435 in reported general payments places this provider in the 90th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 12 | $7,881 |
| Prednisolone Acetate | 95 | $3,876 |
| Mycophenolate Mofetil | 18 | $3,425 |
| Cyclosporine | 12 | $3,398 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $2,389 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $2,144 |
| Latanoprost | 44 | $691 |
| ValacyclovirValacyclovir Hcl | 31 | $641 |
| Ketorolac Tromethamine | 31 | $406 |
| MethotrexateMethotrexate Sodium | 19 | $386 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 29 | $301 |
| Timolol Maleate | 24 | $184 |
| Brimonidine Tartrate | 17 | $150 |
| Naproxen | 12 | $148 |
| Prednisone | 11 | $34 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $1,780 | $10,02523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Cleveland
- Peter KaiserCleveland$1.5M
- Justis EhlersCleveland$639K
- Sunil SrivastavaCleveland$508K
- William WileyCleveland$479K
- Yasha ModiCleveland$234K
- Faruk OrgeCleveland$158K
- Danny MammoCleveland$149K
- Douglas RheeCleveland$138K
- Jeffrey GosheCleveland$82K
- William DuppsCleveland$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.